Fosinopril: Pharmacokinetics and pharmacodynamics in Chinese subjects

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 155-160

  Ding, Philip Y A ^c   Chu, Kai Ming ^a   Hu, Oliver Yoa Pu ^a   Huang, Giang Ming ^a   Jeng, Jing Jen ^a   Chang, Audrey ^b   Delaney, Carol L ^b   MacAskill, Maynard ^b   Yang, B C ^b   Jemal, Mohammed ^b   Smith, Robert ^b   Liao, Wei Chi ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b BRISTOL MYERS SQUIBB   (United States)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FOSINOPRIL; FOSINOPRILAT; PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; FOSINOPRIL; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROTEIN BINDING;

EID: 0032950729     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007705     Document Type: Article

References (20)

1. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M: Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988;25:9-15.
2. Straka RJ, Hansen SR, Benson SR, Walker PF: Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol 1996;36:740-747.
3. Ramirez LF: Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med 1996;63:330-331.
4. Chen WJ, Loh EW, Hsu YP, Chen CC, Yu JM, Cheng AT: Alcohol-metabolising genes and alcoholism among Taiwanese Han men: independent effect of ADH2, ADH3 and ALDH2. Br J Psychiatry 1996;168:762-767.
5. Weerasuriya K, Jayakody RL, Smith CA, Wolf CR, Tucker GT, Lennard MS: Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994;38:466-470.
6. Caraco Y, Tateishi T, Wood AJ: Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995;58:62-72.
7. Lam YW, Jann MW, Chang WH, Yu HS, Lin SK, Chen H, et al: Intra-and interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 1995;35:128-136.
8. Hosseine SJ, Farid R, Ghalighi MR, Feely J: Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration. Ir J Med Sci 1995;164:26-27.
9. He P, Liu GX, Liu ZH, Sun FY, Li CY, Yang Y: Ethnic differences in disposition of antipyrine and acetaminophen between Tibetan and Han healthy volunteers. Yao Hsueh Hsueh Pao 1994;29:566-569.
10. Dahl ML, Johansson I, Yue QY, Sawe J, Bertilsson L, Ingelman-Sundberg M, et al: Interethnic differences in drug oxidation: implications for the utilization of antidepressants and neuroleptics. Clin Neuropharmacol 1992;15(Suppl. 1, Pt. A):88A-89A.
11. Wood AJ, Zhou HH: Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991;20:350-373.
12. Flores-Murrieta FJ, Castaneda-Hernandez G, Herrera JE, Hong E: Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. Arch Med Res 1994;25:381-385.
13. Jhee SS, Burm JP, Gill MA: Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods. Antimicrob Agents Chemother 1994;38:2073-2077.
14. Anderson PJ, Critchley JA, Tomlinson B, Resplandy G: Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Br J Clin Pharmacol 1995;39:361-368.
15. Anderson PJ, Critchley JA, Tomlinson B: A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Eur J Clin Pharmacol 1996;50:57-62.
16. Kostis JB, Garland WT, Delaney C, Norton J, Liao WC: Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure. Clin Pharmacol Ther 1995;58:660-665.
17. Wang-Iverson D, Ivashkiv E, Jemal M, Cohen AI: Simultaneous determination of SQ 28,555 and SQ 27,519 in serum by ionspray mass spectrometry (abstract). Paper presented at the annual meeting of the American Society for Mass Spectrometry, May, Nashville, TN.
18. Rohatgi PK, Ryan JW: Simple radioassay for measuring serum activity of angiotensin-converting enzyme in sarcoidosis. Chest 1980;78:69-76.
19. Locke CS: An exact confidence interval from untransformed date for the ratio of two formulation means. J Pharm Biopharm 1984;12:649-655.
20. Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA: Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects. J Clin Pharmacol 1991;31:58-64.